Epigenomics EBIT/Assets
The Operating Income to Assets Ratio (EBIT/Assets) of Epigenomics (ECX.F) as of Nov 4, 2026 is -9.54 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -58.81 % — a change of -83.77% (higher).
Get this data via API
Financial Data API
EBIT/Assets
-9.54 %
YoY
-83.77%
Last updated:
The Epigenomics EBIT/Assets history
3 Years
10 Years
25 Years
Max
| YEAR | EBIT/Assets | YoY |
|---|---|---|
| -9.54 % | -83.77% | |
| -58.81 % | -29.87% | |
| -83.85 % | +778.51% | |
| -9.54 % | -93.59% | |
| -148.80 % | +37.83% | |
| -107.96 % | +77.28% | |
| -60.90 % | +22.18% | |
| -49.84 % | -26.98% | |
| -68.26 % | -7.31% | |
| -73.64 % | -0.01% | |
| -73.65 % | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Epigenomics Stock analysis
Frequently Asked Questions about Epigenomics stock
Operating Income to Assets Ratio (EBIT/Assets) of Epigenomics is -9.54 % in 2024.
Operating Income to Assets Ratio (EBIT/Assets) of Epigenomics changed from -58.81 % to -9.54 %, representing a -83.77% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Epigenomics since 2006 – with annual values, charts, and detailed analysis.
EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Epigenomics with sector peers and the industry average to assess whether it is attractive.
To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Profitability — Epigenomics
All Key Metrics — Epigenomics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth